Its fourth quarter results are in the books and Paradigm Capital analyst Daniel Rosenberg thinks there is still a lot of ...

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It lead candidate is Zilosul, an injectable pentosan polysulfate ...

Kinetics Paradigm Fund earns an Above Average Process Pillar rating. The predominant contributor to the rating is its parent firm's excellent long-term risk-adjusted performance, as shown by the ...

In a research report to clients March 4, the analyst initiated coverage of CJT with a “Buy” rating and 12-month price target ...